Effect of Zhen-wu decoction on chronic heart failure in rats
Purpose: To investigate the effect of Zhen-wu decoction (ZWD) on oxidative stress and hemodynamics in chronic congestive heart failure (CHF) rats.
Methods: After Sprague Dawley (SD) rats were successfully prepared into CHF, they were randomly divided into normal control group, model (untreated CHF) group, captopril group, high-dose, middledose and low-dose of ZWD groups, and were treated with drugs for 4 weeks respectively. At the end of the experiment, hemodynamic function, whole heart weight index, blood creatinine kinase (CK), superoxide dismutase (SOD), malondialdehyde (MDA), nitric oxide (NO) and nitric oxide synthase (NOS) were determined.
Results: Compared with normal control group, ZWD group showed decreased arterial systolic pressure (SBP, 89.16 ± 17.27 mmHg), diastolic pressure (DBP, 72.54 ± 22.36 mmHg), mean arterial pressure (MAP, 72.64 ± 11.87 mmHg), heart rate (HR, 368.25 ± 39.12 beats/min), left ventricular systolic peak (LVSP, 105.27 ± 15.23 mmHg), and left ventricular pressure change rate (dp/dt max) (p < 0.05), while left ventricular end diastolic pressure (LVEDP) (19.52 ± 1.89 mmHg), whole heart weight index (2.74 ± 0.16 mg/g), blood CK (0.98 ± 0.16 U/mL), MDA (17.28 ± 2.94 nmol/mL), NO (36.35 ± 3.27 umol/L), NOS (39.89 ± 3.56 U/mL) significantly increased (p < 0.05). High dose of ZWD significantly improved hemodynamic function, lowered MDA (8.85 ± 2.14 nmol/mL) and NO (24.25 ± 3.21 umol/L) levels (p < 0.05), and also decreased CK (0.58 ± 0.37 U/mL) and NOS (26.12 ± 3.87 U/mL) in CHF rats (p < 0.05).
Conclusion: ZWD improves adriamycin-induced chronic congestive heart failure in rats significantly, and therefore has potential to be developed for the management of chronic congestive heart failure.
Keywords: Zhen-wu decoction, Chronic heart failure, Hemodynamic function, Oxidative stress
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.